BridgeBio Oncology Therapeutics, Inc.
Public company- Headquarters
- SOUTH SAN FRANCISCO, California
- Ticker
- BBOT
- CIK
- 0001869105
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Chief Medical and Development OfficerYong Ben, M.D., M.B.A. | Nov 5, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive departure
Chief Medical and Development Officer departs: Yong Ben, M.D., M.B.A.
Yong Ben, M.D., M.B.A., Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc., resigns the role, effective January 8, 2027. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 5, 2026Role: Chief Medical and Development Officer
Only one public record so far. We add events as soon as a new filing lands; watch BridgeBio Oncology Therapeutics, Inc. to get them in your digest.
Last verified Nov 8, 2026